ClinicalTrials.gg
CompletedNCT04150861Updated Feb 14, 2023Results posted

Rekovelle PK Trial in Chinese Women

A Phase 1 interventional study of Follitropin Delta in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 1 site in China. Open to female participants aged 21 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by Ferring Pharmaceuticals · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2019, registered Nov 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.

Enrollment
12th of 13
24 · median 220
Started
2019
the only one that year
Phase 1
Only one
of the 13
Registered
8th of 13
by date
Lead sponsor
10 of 13
Ferring Pharmaceuticals

Among the 13 studies testing follitropin delta in Infertility, this one is the 12th largest by enrollment, is the only one that started in 2019, is the only one in phase 1, and was the 8th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About follitropin delta

follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 21 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing follitropin delta in Infertility, or all of them as a file.
02

Study summary

FE 999049 is a gonadotropin preparation containing recombinant human follicle stimulating hormone (rhFSH) under development by Ferring Pharmaceuticals. It is intended for controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. In previous trials the exposure to and dose proportionality of FE 999049 in a clinically relevant dose range in Caucasian and Japanese healthy women have been shown to be very similar. This is a trial in healthy Chinese women investigating the pharmacokinetics, safety, and tolerability of a single subcutaneous dose of FE 999049.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • In vitro fertilisation
  • Controlled ovarian stimulation
04

Who can participate

Ages eligible
21 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female of Chinese origin, with two ethnic Chinese parents and four ethnic Chinese grandparents 21-40 years of age (both inclusive)
  • Willing to stop using combined oral (COC) in relation to the first DECAPEPTYL Depot administration on Day -28
  • Agrees to use a double barrier method of contraception between Day -63 and Day 28, if not abstinent. A double barrier method of contraception should also be used after Day 28 until menses resumes or until another contraceptive method has been established
  • Normal menstrual cycles with a range of 24-35 days in the absence of oral contraceptives
  • Serum FSH less than equal to (≤)5 IU/L on Day -3 and Day -1
  • (BMI) of 18.5 -25 kg/m\^2 (both inclusive)
  • Negative serology for (HIV) antibody, (surface antigen), antibody, and syphilis bacteria
  • Healthy according to medical history, physical examination, gynaecological examination, , blood pressure, and laboratory profile of blood and urine
  • Negative urine drug screen and alcohol breath test at screening and on Day -1
  • Non-smoker or light smoker (≤ 5 cigarettes/day) for at least 6 months prior to trial

Exclusion criteria

Exclusion Criteria:

  • Presence or a history of diseases of the renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems, or presence or history of clinically significant reproductive, psychiatric, immunological, endocrine or metabolic diseases
  • Cancer within the last 5 years except for adequately managed basal cell carcinoma and squamous cell carcinoma of the skin
  • Pregnancy or breastfeeding
  • Current or a history of endocrine abnormalities such as hyperprolactinaemia, polycystic ovary syndrome or other ovarian dysfunction, tumours of the pituitary gland or hypothalamus, thyroid or adrenal disease
  • Clinically significant findings on the trans-vaginal ultrasound, cytology, gynaecological or breast examination at screening or on Day -1 including ovarian cysts or tumours of the ovaries or uterus
  • for the use of gonadotropins and gonadotropin-releasing hormone (GnRH) agonists
  • Previously treated with gonadotropins within the last 6 months prior to screening
  • History within the last two years or current abuse of alcohol or drugs
  • Presence or history of severe allergy or anaphylactic reactions
  • Intake of prescribed medication, over-the-counter (OTC) medication, or herbal medicines, with the exceptions of COC, cromoglycate, and paracetamol according to the labelling, within 2 weeks or 5 half-lives of the drug, whichever is longer, prior to first dose of DECAPEPTYL Depot. Topical treatments of bacterial or fungal infection are allowed if stopped before first dose of IMP
  • Intake of any non-registered drug within the last 12 weeks preceding screening, or longer if judged by the investigator to possibly influence the outcome of the current trial
  • High daily consumption of caffeine-containing beverages (e.g. more than five cups of coffee or equivalent) with a risk of withdrawal symptoms arising during the trial that may confound the safety evaluation
  • Blood donation or major blood loss (greater than equal to [≥]500 mL) within the last 8 weeks, or plasma donation with the last 4 weeks preceding the first day of IMP dosing
  • Current non-smokers or light smoker with a history of long-term, heavy smoking (>10 pack-years)
  • Previously dosed in this trial
  • Mental incapacity or language barrier precluding adequate understanding or co-operation
  • Considered by the investigator to be unsuitable to participate in the trial for any other reason
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Follitropin delta 12 μg

    Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.

    Drug: Follitropin Delta

  • Experimental
    Follitropin delta 18 μg

    Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.

    Drug: Follitropin Delta

  • Experimental
    Follitropin delta 24 μg

    Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.

    Drug: Follitropin Delta

Interventions

  • Solution for Injection, subcutaneous administration

    Also known as: REKOVELLE, FE 999049

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC)

    Area under the concentration-time curve from dosing to infinity.

    Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose

  2. Area Under the Serum Concentration-time Curve From Dosing up to Time t (AUCt)

    AUCt is defined as the area under the serum concentration-time curve from dosing up to time t, where t is the last time point at which the concentration is above the lower limit of quantification.

    Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose

  3. Maximum Serum Concentration Observed (Cmax)

    Maximum concentration observed in serum.

    Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose

  4. Time of Maximum Observed Serum Concentration (Tmax)

    Time of maximum observed concentration in serum.

    Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose

  5. Apparent Total Systemic Clearance (CL/F)

    Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose

  6. Apparent Volume of Distribution Associated With the Terminal Phase (VZ/F)

    Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose

  7. Terminal Elimination Half-life (t½)

    Time frame: At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose

Secondary outcomes

  1. Number of Participants With Clinically Significant Abnormal Changes in Electrocardiogram (ECG)

    Number of participants with clinically significant abnormal changes in ECG are presented.

    Time frame: At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)

  2. Number of Participants With Clinically Significant Abnormal Changes in Vital Signs

    Number of participants with clinically significant abnormal changes in vital signs (systemic blood pressures, heart rate and body temperature) are presented.

    Time frame: At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)

  3. Number of Participants With Clinically Significant Abnormal Findings in Laboratory Parameters

    Number of participants with clinically significant abnormal findings in laboratory parameters (clinical chemistry, haematology, urinalysis) are presented.

    Time frame: At screening, on Day -1 and Day 3, and at the follow-up visit (Day 11)

  4. Number of Participants With Adverse Events (AEs) and Type of AEs

    An AE is any untoward medical occurrence in a participant participating in a clinical trial. Number of participants with any AE (serious or non-serious) and type of AEs ( mild, moderate, severe) are presented.

    Time frame: From signed informed consent until the end-of-trial visit (Day 28)

  5. Frequency of Injection Site Reactions

    The injection site reactions (redness, pain, itching, swelling, and bruising) will be assessed by the investigator after injection, 30 minutes, and 24 hours after administration of the IMP. Each injection site reaction will be assessed as none, mild, moderate, or severe.

    Time frame: Immediately, 30 minutes, and 24 hours after administration

  6. Number of Participants With Treatment-induced Anti-follicle-stimulating Hormone (Anti-FSH) Antibodies

    Time frame: On Day 1 predose, Day 7, and Day 28

07

Results

Posted Dec 24, 2020

Participant flow

The trial was conducted at one site in China between June 2019 to December 2019.

Participant flow — Overall Study
MilestoneFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Started888
Completed888
Not completed000

Outcome measures

PrimaryArea Under the Serum Concentration-time Curve From Dosing to Infinity (AUC)

Area under the concentration-time curve from dosing to infinity.

Time frame:
At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC)
h*ng/mLFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Area Under the Serum Concentration-time Curve From Dosing to Infinity (AUC)41.3 ± 44.362.9 ± 19.783.1 ± 36.6
PrimaryArea Under the Serum Concentration-time Curve From Dosing up to Time t (AUCt)

AUCt is defined as the area under the serum concentration-time curve from dosing up to time t, where t is the last time point at which the concentration is above the lower limit of quantification.

Time frame:
At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Serum Concentration-time Curve From Dosing up to Time t (AUCt)
h*ng/mLFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Area Under the Serum Concentration-time Curve From Dosing up to Time t (AUCt)36.4 ± 38.056.6 ± 18.774.6 ± 35.9
PrimaryMaximum Serum Concentration Observed (Cmax)

Maximum concentration observed in serum.

Time frame:
At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Reported as:
Geometric mean · ng/mL
Maximum Serum Concentration Observed (Cmax)
ng/mLFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Maximum Serum Concentration Observed (Cmax)0.388 ± 26.50.677 ± 29.10.825 ± 34.6
PrimaryTime of Maximum Observed Serum Concentration (Tmax)

Time of maximum observed concentration in serum.

Time frame:
At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Reported as:
Median · hour
Time of Maximum Observed Serum Concentration (Tmax)
hourFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Time of Maximum Observed Serum Concentration (Tmax)24.0 (16.0 to 36.0)24.0 (16.0 to 48.0)24.0 (24.0 to 28.0)
PrimaryApparent Total Systemic Clearance (CL/F)
Time frame:
At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Reported as:
Geometric mean · Liter/hour
Apparent Total Systemic Clearance (CL/F)
Liter/hourFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Apparent Total Systemic Clearance (CL/F)0.301 ± 46.60.286 ± 19.70.289 ± 36.6
PrimaryApparent Volume of Distribution Associated With the Terminal Phase (VZ/F)
Time frame:
At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution Associated With the Terminal Phase (VZ/F)
LiterFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Apparent Volume of Distribution Associated With the Terminal Phase (VZ/F)25.5 ± 19.520.8 ± 43.525.4 ± 31.5
PrimaryTerminal Elimination Half-life (t½)
Time frame:
At -1, -0.5 and 0 hour predose, and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48 hours, and 3, 4, 5, 6, 7, 8, and 9 days postdose
Reported as:
Geometric mean · hour
Terminal Elimination Half-life (t½)
hourFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Terminal Elimination Half-life (t½)58.6 ± 47.550.5 ± 43.560.9 ± 13.6
SecondaryNumber of Participants With Clinically Significant Abnormal Changes in Electrocardiogram (ECG)

Number of participants with clinically significant abnormal changes in ECG are presented.

Time frame:
At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Changes in Electrocardiogram (ECG)
ParticipantsFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Number of Participants With Clinically Significant Abnormal Changes in Electrocardiogram (ECG)001
SecondaryNumber of Participants With Clinically Significant Abnormal Changes in Vital Signs

Number of participants with clinically significant abnormal changes in vital signs (systemic blood pressures, heart rate and body temperature) are presented.

Time frame:
At screening, on Day -1, at 12, 24, 48 hours postdose, and at the follow-up visit (Day 11)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Changes in Vital Signs
ParticipantsFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Number of Participants With Clinically Significant Abnormal Changes in Vital Signs000
SecondaryNumber of Participants With Clinically Significant Abnormal Findings in Laboratory Parameters

Number of participants with clinically significant abnormal findings in laboratory parameters (clinical chemistry, haematology, urinalysis) are presented.

Time frame:
At screening, on Day -1 and Day 3, and at the follow-up visit (Day 11)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Findings in Laboratory Parameters
ParticipantsFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Clinical Chemistry211
Haematology010
Urinalysis010
SecondaryNumber of Participants With Adverse Events (AEs) and Type of AEs

An AE is any untoward medical occurrence in a participant participating in a clinical trial. Number of participants with any AE (serious or non-serious) and type of AEs ( mild, moderate, severe) are presented.

Time frame:
From signed informed consent until the end-of-trial visit (Day 28)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Type of AEs
ParticipantsFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Adverse events (AEs)543
Serious AEs000
Mild AEs533
Moderate AEs010
Severe AEs000
SecondaryFrequency of Injection Site Reactions

The injection site reactions (redness, pain, itching, swelling, and bruising) will be assessed by the investigator after injection, 30 minutes, and 24 hours after administration of the IMP. Each injection site reaction will be assessed as none, mild, moderate, or severe.

Time frame:
Immediately, 30 minutes, and 24 hours after administration
Reported as:
Count of participants · Participants
Frequency of Injection Site Reactions
ParticipantsFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Frequency of Injection Site Reactions000
SecondaryNumber of Participants With Treatment-induced Anti-follicle-stimulating Hormone (Anti-FSH) Antibodies
Time frame:
On Day 1 predose, Day 7, and Day 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment-induced Anti-follicle-stimulating Hormone (Anti-FSH) Antibodies
ParticipantsFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Number of Participants With Treatment-induced Anti-follicle-stimulating Hormone (Anti-FSH) Antibodies000

Adverse events

Collected over From signed informed consent until the end-of-trial visit (Day 28). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Follitropin Delta (FE 999049) 12 μg0/8 (0%)0/8 (0%)5/8 (62.5%)
Follitropin Delta (FE 999049) 18 μg0/8 (0%)0/8 (0%)4/8 (50%)
Follitropin Delta (FE 999049) 24 μg0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventFollitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μg
Ventricular extrasystolesCardiac disorders0/80/81/8
Procedural dizzinessInjury, poisoning and procedural complications1/80/80/8
Alanine aminotransferase increasedInvestigations1/81/80/8
Aspartate aminotransferase increasedInvestigations1/81/80/8
Blood urine presentInvestigations1/81/80/8
Neutrophil count decreasedInvestigations0/81/80/8
Red blood cells urine positiveInvestigations0/80/81/8
Smear cervix abnormalInvestigations0/80/81/8
White blood cell count decreasedInvestigations0/81/80/8
Poor quality sleepNervous system disorders1/80/81/8

Baseline characteristics

The full analysis set (FAS) comprised data from all dosed subjects. Subjects were analyzed according to the actual dose received.

Age, Continuous
Age, Continuous(years)Follitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μgTotal
Mean28.6 ± 6.029.5 ± 6.725.4 ± 4.627.8 ± 5.8
Sex: Female, Male
Sex: Female, Male(Participants)Follitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μgTotal
Female88824
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Follitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μgTotal
Hispanic or Latino0000
Not Hispanic or Latino88824
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Follitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μgTotal
American Indian or Alaska Native0000
Asian88824
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Follitropin Delta (FE 999049) 12 μgFollitropin Delta (FE 999049) 18 μgFollitropin Delta (FE 999049) 24 μgTotal
Mean22.2 ± 1.620.7 ± 1.922.0 ± 2.321.6 ± 2.0
08

Study locations

1 site
  • First Hospital Affiliated to Nanjing Medical University Jiangsu Province Hospital
    Nanjing, China
09

References and documents

Publications

  • Shao F, Jiang Y, Ding S, Larsson P, Pinton P, Jonker DM. Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women. Clin Drug Investig. 2023 Jan;43(1):37-44. doi: 10.1007/s40261-022-01232-9. Epub 2022 Dec 7. PubMed 36478528 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Nov 2019, 5 months.

Results were first posted in Dec 2020, 1 year after primary completion.

Of 28 phase 1 interventional studies under Infertility, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2019
First posted
Nov 5, 2019
StartActual
Jun 23, 2019
Primary completionActual
Nov 28, 2019
CompletionActual
Dec 16, 2019
Results first posted
Dec 24, 2020
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04150861
Responsible party
Sponsor
First posted
Nov 5, 2019
Start date
Jun 23, 2019
Primary completion
Nov 28, 2019
Completion
Dec 16, 2019
Results posted
Dec 24, 2020
Last update
Feb 14, 2023

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion